Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 18

1438P - First-line (1L) zolbetuximab + chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT + GLOW

Date

14 Sep 2024

Session

Poster session 18

Topics

Tumour Site

Gastric Cancer;  Gastro-Oesophageal Junction Cancer

Presenters

Yoon-Koo Kang

Citation

Annals of Oncology (2024) 35 (suppl_2): S878-S912. 10.1016/annonc/annonc1603

Authors

Y. Kang1, M.A. Shah2, K. Shitara3, J.A. Ajani4, F. Lordick5, E. Van Cutsem6, D.H. Ilson7, S.J. Klempner8, K. Yamaguchi9, T. Nakajima10, Y.J. Cao11, R. Li12, D. Moran11, R.R. Pophale13, R. Ranganath14, R. Xu15

Author affiliations

  • 1 Oncology Dept, Asan Medical Center - University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 2 Medical Oncology And Hematology Department, Weill Cornell Medical College, NY/US
  • 3 Department Of Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 4 Gi Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 5 Medicine Department, Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, 04103 - Leipzig/DE
  • 6 Digestive Oncology Department, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, 3000 - Leuven/BE
  • 7 Medicine Department, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, 10065 - New York/US
  • 8 Medical Oncology Department, MGH - Massachusetts General Hospital, 02114 - Boston/US
  • 9 Gastroenterological Chemotherapy Dept., The Cancer Institute Hospital of JFCR, 135-8550 - Koto-ku/JP
  • 10 Medicine Department, Astellas Pharma Global Development, 60062 - Northbrook/US
  • 11 Data Science, Astellas Pharma Global Development, Inc., Northbrook/US
  • 12 Data Science, Astellas Pharma Global Development, Northbrook/US
  • 13 Medical Affairs Department, Astellas Pharma Global Development, Inc., Northbrook/US
  • 14 Medical Affairs Department, Astellas Pharma Global Development, Inc., 60062 - Northbrook/US
  • 15 Medical Oncology Dept, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1438P

Background

SPOTLIGHT and GLOW showed improved progression-free and overall survival (PFS, OS) with 1L zolbetuximab + chemotherapy vs placebo + chemotherapy in pts with CLDN18.2+, HER2–, LA unresectable or mG/GEJ adenocarcinoma at interim and updated analyses. Here we present the pooled final OS analysis.

Methods

Pts were randomly assigned 1:1 to zolbetuximab IV (800 mg/m2 cycle 1 day 1, then 600 mg/m2 every 3 weeks) + chemotherapy (SPOTLIGHT, mFOLFOX6: folinic acid, fluorouracil, oxaliplatin IV every 2 weeks; GLOW, CAPOX: capecitabine twice daily days 1–14, oxaliplatin IV every 3 weeks) or placebo + chemotherapy for four 42-day cycles (SPOTLIGHT) or eight 21-day cycles (GLOW). Pts continued zolbetuximab/placebo, + capecitabine (GLOW) or + folinic acid + fluorouracil (SPOTLIGHT) per investigator decision, until progressive disease (PD) or discontinuation criteria were met. Endpoints included PFS (primary), OS (key secondary), and objective response rate (ORR)/safety (secondary).

Results

The addition of zolbetuximab continued to improve both PFS and OS at final analysis (n=1072; Table). The most common treatment-emergent adverse events (TEAEs) with zolbetuximab + chemotherapy were nausea (76.0% vs 56.2% in zolbetuximab vs placebo arms), vomiting (66.8% vs 34.2%), and decreased appetite (45.2% vs 34.7%); serious TEAEs (48.0% vs 48.4%), grade ≥3 TEAEs (80.7% vs 74.8%), and drug-related TEAEs leading to death (2.1% vs 2.3%) were similar in both arms. Table: 1438P

Zolbetuximab + chemotherapy Placebo + chemotherapy
PFS
Median, mo (95% CI) 9.2 (8.4–10.4) 8.2 (7.6–8.4)
HRa (95% CI); 1-sided P value 0.71 (0.61–0.83);

Conclusions

Zolbetuximab + chemotherapy continued to demonstrate statistically significant and clinically meaningful improvement in PFS and OS vs placebo + chemotherapy, with no new safety signals—supporting zolbetuximab + chemotherapy as a new standard for 1L treatment of pts with CLDN18.2+, HER2–, LA unresectable or mG/GEJ adenocarcinoma.

Clinical trial identification

NCT03504397; NCT03653507.

Editorial acknowledgement

Medical writing support was provided by Ann Ferguson, PhD, of Oxford PharmaGenesis Inc.

Legal entity responsible for the study

Astellas Pharma Inc.

Funding

Astellas Pharma Inc.

Disclosure

Y. Kang: Financial Interests, Personal, Advisory Board: ALX Oncology, Zymeworks, Amgen, Novartis, Macrogenics, Daehwa, Blueprint, Surface Oncology, BMS, Merck, Roche, Liscure. M.A. Shah: Financial Interests, Personal, Funding: Merck, Bristol Myers Squibb, Oncolys Biopharma. K. Shitara: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Takeda, Ono Pharmaceutical, MSD, Novartis, Daiichi Sankyo, Amgen, Guardant Health Japan Corp, Astellas Pharma Inc., Astellas, Bayer, AstraZeneca, Zymeworks Biopharmaceuticals Inc., ALX Oncology Inc.; Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Janssen, AstraZeneca, Eli Lilly, Astellas, Ono Pharmaceutical; Financial Interests, Institutional, Research Grant: Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharmaceutical, MSD, Eisai, Amgen, PRA Health Sciences. J.A. Ajani: Financial Interests, Personal, Advisory Board: BMS, Gilead, Astellas, AZ, Jazz, KirinKyowa, Servier, BeiGene, Daiichi Sankyo; Financial Interests, Institutional, Coordinating PI, My institution receives funding: BMS; Financial Interests, Institutional, Coordinating PI: Merck, Jazz, Astellas, DeltaFly, Gilead, Roche. F. Lordick: Financial Interests, Personal, Advisory Board: Amgen, Astellas, BMS, Bayer, BeiGene, BioNTech, Eli Lilly, Elsevier, MSD, Novartis, Roche, Daiichi Sankyo, PAGE; Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, Eli Lilly, Imedex, Incyte, MSD, MedUpdate, Medscape, Merck Serono, Roche, Servier, StreamedUp!, Daiichi Sankyo, Novartis, Art Tempi; Financial Interests, Personal, Writing Engagement: Deutscher Ärzteverlag, Iomedico, Springer-Nature; Financial Interests, Institutional, Research Grant: BMS, Gilead. E. Van Cutsem: Financial Interests, Personal, Advisory Board: AbbVie, Agenus, ALX, Arcus Biosciences, Astellas, AstraZeneca, Bayer, BeiGene, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, Elmedix, Eisai, GSK, Hoopika Biotech, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Seattle Genetics, Servier, Simcere, Takeda, Taiho, Terumo; Financial Interests, Personal, Invited Speaker: Amgen, Pfizer. S.J. Klempner: Financial Interests, Personal, Advisory Board, Stomach Cancer Advisory Board: Merck, Bristol Myers Squibb, Astellas, Daiichi Sankyo; Financial Interests, Personal, Advisory Board, One Time Advisory Board: Natera; Financial Interests, Personal, Advisory Board, Stomach cancer advisory board x 1, 2023: Mersana; Financial Interests, Personal, Advisory Board, Stomach cancer advisory board x 1: Sanofi-Aventis; Financial Interests, Personal, Advisory Board, Stomach Cancer consulting, ended in 1/2024: Novartis; Financial Interests, Personal, Advisory Board, Stomach cancer advisory board x1 in 1/2024: AstraZeneca; Financial Interests, Personal, Advisory Board, Stomach cancer advisory board x1 in 3/2024: I-Mab Therapeutics; Financial Interests, Personal, Advisory Board, Stomach cancer consulting, <$1,500 USD in 2023: Taiho Oncology; Financial Interests, Personal, Advisory Board, Stomach cancer advisory board x1, planned for 6/2024: Eisai; Financial Interests, Personal, Stocks/Shares, Stock Ownership, ended in 6/2022: Turning Point Therapeutics; Financial Interests, Personal, Stocks/Shares, Early investor, company is not public: MBrace; Financial Interests, Institutional, Coordinating PI, National PI for trial: Leap Therapeutics; Financial Interests, Personal and Institutional, Local PI, Local PI for trial, also served on advisory board as noted above: Astellas; Financial Interests, Institutional, Local PI, Ended in 2022: Macrogenics; Financial Interests, Institutional, Coordinating PI, Trial PI, ended in 2023: Silverback; Financial Interests, Institutional, Local PI, Site PI for phase III trials: Arcus; Financial Interests, Personal and Institutional, Local PI, Site PI for trial, as disclosed above was a one-time advisory board participant, <$5,000 USD: I-Mab; Non-Financial Interests, Advisory Role, Medical-Scientific Advisory Board Member: Debbies Dream Foundation; Non-Financial Interests, Advisory Role, Member of Scientific Advisory Board: Hope for Stomach Cancer; Non-Financial Interests, Other, Member of Gastric and Esophageal NCCN Guideline Committees: NCCN; Other, Participant in gastroesophageal CME activities, compensated, last in 3/2024: Research to Practice. K. Yamaguchi: Financial Interests, Personal, Expert Testimony: Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K. Takeda Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd. Bristol Myers Squibb K.K., Takeda Pharmaceutical Co., Ltd. T. Nakajima, Y.J. Cao, R. Li, R.R. Pophale: Financial Interests, Personal, Full or part-time Employment: Astellas. R. Xu: Financial Interests, Personal, Invited Speaker: BMS, MSD, Hutchison Pharm; Financial Interests, Personal, Advisory Board: Henrui, BeiGene, Astalas, Merck, Junshi, Innovent, Keymed Biosience. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.